The European market has shown resilience, with the STOXX Europe 600 Index ending higher, buoyed by robust economic data and mixed earnings results across major stock indexes. Amid this backdrop, the concept of penny stocks remains pertinent as these smaller or newer companies can offer unique growth opportunities. While the term might seem outdated, penny stocks continue to capture investor interest due to their potential for significant returns when backed by strong financials and fundamentals.

B+S Banksysteme's (ETR:DTD2) stock is up by a considerable 12% over the past month. As most would know, fundamentals...

Despite posting healthy earnings, B+S Banksysteme Aktiengesellschaft's ( ETR:DTD2 ) stock has been quite weak. Along...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.